Abstract
The modern concept of stress is based on responses to events or factors (“stressors”) experienced as aversive, threatening or excessive for maintaining physiological equilibrium of an organism. Prolonged exposure to stressors, particularly during early life, is strongly associated with later psychiatric disorders. Underlying mechanistic connections between stress responses and development of psychiatric illnesses remain uncertain and typically appear to be nonspecific. Relevant candidate mechanisms are likely to include the hypothalamic-pituitary-adrenal (HPA) axis, marked by sustained excessive release of cortisol from the adrenal cortex. In turn, this process is influenced by and alters various central neurotransmitter and other molecular signaling systems that include glutamate, dopamine, serotonin, and neurotrophic peptides. A dditional manifestations of stress include altered neurogenesis and neuroplasticity, as well as oxidative neuron-damaging effects. The complex molecular systems involved in these processes present many opportunities for innovative pharmacological interventions that may have preventive or therapeutic benefits regarding mental illnesses arising from stress.
Keywords: Early life stress, HPA axis, glucocorticoids, neuroplasticity, neurogenesis.
Current Pharmaceutical Design
Title:Early-Life Stress and Psychiatric Disorders: Epidemiology, Neurobiology and Innovative Pharmacological Targets
Volume: 21 Issue: 11
Author(s): A. Ventriglio, A. Gentile, R.J. Baldessarini and A. Bellomo
Affiliation:
Keywords: Early life stress, HPA axis, glucocorticoids, neuroplasticity, neurogenesis.
Abstract: The modern concept of stress is based on responses to events or factors (“stressors”) experienced as aversive, threatening or excessive for maintaining physiological equilibrium of an organism. Prolonged exposure to stressors, particularly during early life, is strongly associated with later psychiatric disorders. Underlying mechanistic connections between stress responses and development of psychiatric illnesses remain uncertain and typically appear to be nonspecific. Relevant candidate mechanisms are likely to include the hypothalamic-pituitary-adrenal (HPA) axis, marked by sustained excessive release of cortisol from the adrenal cortex. In turn, this process is influenced by and alters various central neurotransmitter and other molecular signaling systems that include glutamate, dopamine, serotonin, and neurotrophic peptides. A dditional manifestations of stress include altered neurogenesis and neuroplasticity, as well as oxidative neuron-damaging effects. The complex molecular systems involved in these processes present many opportunities for innovative pharmacological interventions that may have preventive or therapeutic benefits regarding mental illnesses arising from stress.
Export Options
About this article
Cite this article as:
Ventriglio A., Gentile A., Baldessarini R.J. and Bellomo A., Early-Life Stress and Psychiatric Disorders: Epidemiology, Neurobiology and Innovative Pharmacological Targets, Current Pharmaceutical Design 2015; 21 (11) . https://dx.doi.org/10.2174/1381612821666150105121244
DOI https://dx.doi.org/10.2174/1381612821666150105121244 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Potential of Cannabinoids in Schizophrenia
Recent Patents on CNS Drug Discovery (Discontinued) Depression in Coronary Heart Disease Patients: Etiological and Screening Issues
Current Psychiatry Reviews Neuroimaging of the Serotonin Transporter: Possibilities and Pitfalls
Current Psychiatry Reviews Edema, Inflammation and Fibrosis – Comparison Between Catecholamine- and Hypoxia-Induced Pulmonary Injuries
Vascular Disease Prevention (Discontinued) Machine Learning Approaches in Parkinson’s Disease
Current Medicinal Chemistry Treatment of Acute Leukaemias with Monoclonal Antibodies: Current Status and Future Prospects
Cardiovascular & Hematological Agents in Medicinal Chemistry Estrogen, A Double-Edged Sword: Modulation of TH1- and TH2-Mediated Inflammations by Differential Regulation of TH1 / TH2 Cytokine Production
Current Drug Targets - Inflammation & Allergy Recent Patents, Regulatory Issues, and Toxicity of Nanoparticles in Neuronal Disorders
Current Drug Metabolism The Emerging Role of Metabotropic Glutamate Receptors in the Pathophysiology of Chronic Stress-Related Disorders
Current Neuropharmacology The Heart in Sepsis: From Basic Mechanisms to Clinical Management
Current Vascular Pharmacology Craniofacial Anomalies: From Development to Molecular Pathogenesis
Current Molecular Medicine Statins and Carotid Intima-Media Thickness Reduction: An Up-to-Date Review
Current Medicinal Chemistry A Valuable Animal Model of Spinal Cord Injury to Study Motor Dysfunctions, Comorbid Conditions, and Aging Associated Diseases
Current Pharmaceutical Design Chemical and Pharmacological Chaperones: Application for Recombinant Protein Production and Protein Folding Diseases
Current Medicinal Chemistry Current Status of the Non-nucleoside Reverse Transcriptase Inhibitors of Human Immunodeficiency Virus Type 1
Current Topics in Medicinal Chemistry TGFb and its Smad Connection to Cancer
Current Genomics Receptor-Based Design of Cytokine Therapeutics
Current Pharmaceutical Biotechnology AMPA Receptor Positive Allosteric Modulators: Potential for the Treatment of Neuropsychiatric and Neurological Disorders
Current Topics in Medicinal Chemistry Ovarian Hyperstimulation Syndrome: The Best Approaches for Preven-tion and Treatment: A Mini-Review
Current Women`s Health Reviews Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Assessment of Response to Treatment and Follow-Up in Gastroenteropancreatic Neuroendocrine Neoplasms
Endocrine, Metabolic & Immune Disorders - Drug Targets